These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 9096181)
1. Susceptibility of Pseudomonas aeruginosa of various pyocin types to the newly synthesized ampicillin derivative, N-(6,7-difluoroquinolonyl)ampicillin. Chen CH; Tsou TL; Chiang HY; Lee SH; Lee F; Lee JH; Wang TM; Liu YT J Antimicrob Chemother; 1997 Mar; 39(3):325-30. PubMed ID: 9096181 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antipseudomonal activity, acute toxicity, and mode of action of a newly synthesized fluoroquinolonyl ampicillin derivative. Lin WP; Ji DD; Shiau CY; Yang TC; Yang YW; Tsou TL; Tang ST; Chen CH; Liu YT J Lab Clin Med; 2003 Sep; 142(3):158-65. PubMed ID: 14532903 [TBL] [Abstract][Full Text] [Related]
3. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Kresken M; Wiedemann B Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353 [TBL] [Abstract][Full Text] [Related]
4. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients. Guimaraes MA; Noone P J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708 [TBL] [Abstract][Full Text] [Related]
5. Relationship of antibiotic resistance phenotype to the R-pyocin susceptibility pattern in clinical isolates of Pseudomonas aeruginosa. Tzouvelekis LS; Tumah H; Malliara K; Legakis NJ J Chemother; 1989 Aug; 1(4):226-30. PubMed ID: 2509643 [TBL] [Abstract][Full Text] [Related]
6. [Development and current status of Pseudomonas aeruginosa sensitivity to antibiotics]. Duval J; Soussy CJ Presse Med; 1984 Mar; 13(13):763-7. PubMed ID: 6231591 [TBL] [Abstract][Full Text] [Related]
7. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates. Bassey CM; Baltch AL; Smith RP J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401 [TBL] [Abstract][Full Text] [Related]
8. Fis Contributes to Resistance of Pseudomonas aeruginosa to Ciprofloxacin by Regulating Pyocin Synthesis. Long Y; Fu W; Wang S; Deng X; Jin Y; Bai F; Cheng Z; Wu W J Bacteriol; 2020 May; 202(11):. PubMed ID: 32205461 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Downs J; Andriole VT; Ryan JL Antimicrob Agents Chemother; 1982 Apr; 21(4):670-2. PubMed ID: 6211142 [TBL] [Abstract][Full Text] [Related]
10. Pyocin types of clinical strains of Pseudomonas aeruginosa isolated in Morelia, México (1980-1984). Cervantes Vega C; Chávez J; Padilla ME; Rivera AN; Vaca S Rev Latinoam Microbiol; 1986; 28(4):287-91. PubMed ID: 3108986 [No Abstract] [Full Text] [Related]
11. Acquisition and epidemiology of antibiotic-resistant Escherichia coli in a cohort of newborn calves. Hoyle DV; Knight HI; Shaw DJ; Hillman K; Pearce MC; Low JC; Gunn GJ; Woolhouse ME J Antimicrob Chemother; 2004 May; 53(5):867-71. PubMed ID: 15056641 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of apalcillin alone and in combination with four aminoglycoside antibiotics against Pseudomonas aeruginosa. Höffler U Chemotherapy; 1986; 32(3):255-9. PubMed ID: 3086049 [TBL] [Abstract][Full Text] [Related]
13. Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains. Forward KR; Harding GK; Gray GJ; Urias BA; Ronald AR Antimicrob Agents Chemother; 1983 Oct; 24(4):602-4. PubMed ID: 6228193 [TBL] [Abstract][Full Text] [Related]
14. SOS-Independent Pyocin Production in P. aeruginosa Is Induced by XerC Recombinase Deficiency. Baggett NS; Bronson AS; Cabeen MT mBio; 2021 Dec; 12(6):e0289321. PubMed ID: 34809462 [TBL] [Abstract][Full Text] [Related]
15. A predicted S-type pyocin shows a bactericidal activity against clinical Pseudomonas aeruginosa isolates through membrane damage. Ling H; Saeidi N; Rasouliha BH; Chang MW FEBS Lett; 2010 Aug; 584(15):3354-8. PubMed ID: 20580355 [TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones. Neu HC J Antimicrob Chemother; 1985 Jul; 16(1):43-8. PubMed ID: 3862659 [TBL] [Abstract][Full Text] [Related]
17. Discovery, characterization and in vivo activity of pyocin SD2, a protein antibiotic from Pseudomonas aeruginosa. McCaughey LC; Josts I; Grinter R; White P; Byron O; Tucker NP; Matthews JM; Kleanthous C; Whitchurch CB; Walker D Biochem J; 2016 Aug; 473(15):2345-58. PubMed ID: 27252387 [TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants. Cullmann W; Stieglitz M; Baars B; Opferkuch W Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025 [TBL] [Abstract][Full Text] [Related]
19. Serological and pyocin typing and antibiotic sensitivity of Pseudomonas aeruginosa strains. Del Piano M; La Palombara P; Picci A; Nicosia R Microbiologica; 1986 Apr; 9(2):253-8. PubMed ID: 3086671 [TBL] [Abstract][Full Text] [Related]
20. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid. Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]